Coagulation in Colorectal cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON22944

Enrollment

300

Registered

2009-04-22

Start date

2009-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer, colorectaal carcinoom, coagulation, stolling, angiogenesis, angiogenese, thrombosis, trombose, prognosis, prognose

Interventions

N/A, observational study.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients newly diagnosed with colorectal cancer who have not yet been treated; 2. Any disease stage; 3. Age 18 years or older.

Exclusion criteria

Exclusion criteria: 1. Second primary tumor in the past 5 years, except basal cell carcinoma and in situ carcinomas; 2. Not able to give written informed consent.

Design outcomes

Primary

Measure	Time frame
Primary Objective: the association between tissue factor positive microparticles level in colorectal cancer patients and time to progressive disease.	—

Secondary

Measure	Time frame
Secondary Objectives: 1. The association between the other chosen markers (thrombomodulin, vWf, tissue factor, cancer procoagulant, thrombin generation, PAP-complex, PAI-1, d-dimer, P-selectin, VEGF, Thrombospondi1, CRP) and time to progressive disease; 2. The association between the chosen markers and the occurrence of a VTE; 3. The association between the chosen markers and disease stage; 4. The association between the chosen markers and the use of chemotherapy; 5. The association between the chosen markers and the use of bevacizumab.	—

Measure

Time frame

Secondary Objectives: 1. The association between the other chosen markers (thrombomodulin, vWf, tissue factor, cancer procoagulant, thrombin generation, PAP-complex, PAI-1, d-dimer, P-selectin, VEGF, Thrombospondi1, CRP) and time to progressive disease; 2. The association between the chosen markers and the occurrence of a VTE; 3. The association between the chosen markers and disease stage; 4. The association between the chosen markers and the use of chemotherapy; 5. The association between the chosen markers and the use of bevacizumab.

—

Contacts

Public ContactJ.H.M.J. Vestjens

MD Department of internal medicine, Division medical oncologyMaastricht, University Medical Centre Maastricht, P.O.Box 5800

h.vestjens@mumc.nl+31 (0)43 3877025

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)